J&J to begin human trial of COVID-19 vaccine in U.S. and Belgium
Category: #health  By Mateen Dalal  Date: 2020-06-12
  • share
  • Twitter
  • Facebook
  • LinkedIn

J&J to begin human trial of COVID-19 vaccine in U.S. and Belgium

Johnson & Johnson, a multinational medical device & pharmaceuticals company, has recently announced its plan to commence the human trial of a potential COVID-19 vaccine by the 2nd half of July 2020. The drug maker has been focusing on giving its contribution to the global fight against the deadly coronavirus pandemic.

Additionally, J&J has inked deals with the U.S. government to enhance the manufacturing capacity to develop more than 1 billion vaccine doses prior to the confirmation of its effectiveness.

No COVID-19 vaccines or treatments have been approved across the globe to date. The company will primarily conduct a placebo-controlled trial to examine the safety and immune response of the vaccine among 1,045 healthy candidates aged between 18 to 55 years, including 65 years and older. This vaccine trial will be conducted in Belgium and the United States.

According to Paul Stoffels, Chief Scientific Officer of J&J, the acceleration of the company’s clinical development can be attributed to the preclinical data strength and its interactions with various regulatory bodies.

The drug maker is in talks with the NIAID (National Institutes of Allergy & Infectious Diseases) to initiate the late-stage studies ahead of schedule. This will be dependent on the regulatory approval and the results obtained from early trials.

Moderna Inc. is leading the vaccine development process for coronavirus and has begun testing its vaccine candidate in a mid-stage study among 600 patients. The company expects the commencement of the late-stage trials in July. Its vaccine adopts mRNA technology. On the other hand, J&J is deploying the same tech used in developing its Ebola vaccine.

Currently, there are around 10 vaccines for COVID-19 that are under the human trial phase. Experts have predicted that the development of an effective and safe vaccine could take nearly 12 to 18 months from the beginning of the development process.

Shares of J&J have recently been increased by 1.1% to $147.67.

Source credit:

https://economictimes.indiatimes.com/news/international/business/johnson-johnson-to-begin-human-trials-of-covid-19-vaccine-in-the-second-half-of-july/articleshow/76305716.cms

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

Alphabet’s Google to face lawsuit from NLRB for violating labor laws
Alphabet’s Google to face lawsuit from NLRB for violating labor laws
By Mateen Dalal

In a recent turn of events, U.S. government body National Labor Relations Board (NLRB) has reportedly issued a complaint against American multinational technology company, Google LLC for unlawfully monitoring as well as questioning its workers and su...

Britain’s CMA to levy tougher competition rules on Google and Facebook
Britain’s CMA to levy tougher competition rules on Google and Facebook
By Mateen Dalal

Facebook and Google accounted for around 80% of the total 14 billion pounds spent on digital advertising in 2019. MOW has reportedly accused Google of modifying its Chromium developer tools and Chrome browser to get greater control over advertiser...

Amazon, U.S. Government team up to prevent sale of counterfeit goods
Amazon, U.S. Government team up to prevent sale of counterfeit goods
By Mateen Dalal

According to reliable sources, Washington-headquartered American multinational technology company, Amazon.com Inc has reportedly initiated a joint venture with the U.S. government’s counterfeit agency, the IPR Center (National Intellectual Prop...